# A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance

> **NCT03114865** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 44 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- B-cell Non Hodgkin Lymphoma
- Pre B-Cell Acute Lymphoblastic Leukaemia

## Interventions

- **DRUG:** Blinatumomab 9ug
- **DRUG:** Blinatumomab 28 ug
- **DRUG:** Blinatumomab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03114865
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-05
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03114865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03114865, "A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03114865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*